DNA-Dependent Binding of Nargenicin to DnaE1 Inhibits Replication in .

ACS infectious diseases, Volume: 8, Issue: 3
March 11, 2022
Melissa D Chengalroyen MD, Mandy K Mason MK, Alessandro Borsellini A, Raffaella Tassoni R, Garth L Abrahams GL, Sasha Lynch S, Yong-Mo Ahn YM, Jon Ambler J, Katherine Young K, Brendan M Crowley BM, David B Olsen DB, Digby F Warner DF, Clifton E Barry Iii CE, Helena I M Boshoff HIM, Meindert H Lamers MH, Valerie Mizrahi V

Natural products provide a rich source of potential antimicrobials for treating infectious diseases for which drug resistance has emerged. Foremost among these diseases is tuberculosis. Assessment of the antimycobacterial activity of nargenicin, a natural product that targets the replicative DNA polymerase of , revealed that it is a bactericidal genotoxin that induces a DNA damage response in () and inhibits growth by blocking the replicative DNA polymerase, DnaE1. Cryo-electron microscopy revealed that binding of nargenicin to DnaE1 requires the DNA substrate such that nargenicin is wedged between the terminal base pair and the polymerase and occupies the position of both the incoming nucleotide and templating base. Comparative analysis across three bacterial species suggests that the activity of nargenicin is partly attributable to the DNA binding affinity of the replicative polymerase. This work has laid the foundation for target-led drug discovery efforts focused on DnaE1.

Courtesy of the U.S. National Library of Medicine